Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lukas Kenner

Showing results (251-260 of 267) with videos related to

Pageof 27
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|February 19, 2021
Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentationYixuan Zhou, Ingmar Niels Bastian, Mark D Long, et al.
Haematologica|April 25, 2020
Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic targetHugo Larose, Nina Prokoph, Jamie D Matthews, et al.
Molecular Cancer|May 29, 2024
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progressionTorben Redmer, Martin Raigel, Christina Sternberg, et al.
Cell|July 5, 2014
Heme oxygenase-1 drives metaflammation and insulin resistance in mouse and manAlexander Jais, Elisa Einwallner, Omar Sharif, et al.
The Lancet. Haematology|November 21, 2017
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot studyBerend Snijder, Gregory I Vladimer, Nikolaus Krall, et al.
International Journal of Cancer|October 9, 2020
Thyroid and androgen receptor signaling are antagonized by μ-Crystallin in prostate cancerOsman Aksoy, Jan Pencik, Markus Hartenbach, et al.
Nature Medicine|October 16, 2012
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomasDaniela Laimer, Helmut Dolznig, Karoline Kollmann, et al.
Haematologica|May 25, 2019
High activation of STAT5A drives peripheral T-cell lymphoma and leukemiaBarbara Maurer, Harini Nivarthi, Bettina Wingelhofer, et al.
Cancer Cell|April 16, 2015
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphomaRamona Crescenzo, Francesco Abate, Elena Lasorsa, et al.
Molecular Cancer|October 15, 2025
Thyroid hormone receptor beta signaling is a targetable driver of prostate cancer growthAleksandra Fesiuk, Daniel Pölöske, Elvin D de Araujo, et al.
Pageof 27

Showing results (251-260 of 267) with videos related to

Sort By:
Pageof 27
Proceedings of the National Academy of Sciences of the United States of America|February 19, 2021
Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentationYixuan Zhou, Ingmar Niels Bastian, Mark D Long, et al.
Haematologica|April 25, 2020
Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic targetHugo Larose, Nina Prokoph, Jamie D Matthews, et al.
Molecular Cancer|May 29, 2024
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progressionTorben Redmer, Martin Raigel, Christina Sternberg, et al.
Cell|July 5, 2014
Heme oxygenase-1 drives metaflammation and insulin resistance in mouse and manAlexander Jais, Elisa Einwallner, Omar Sharif, et al.
The Lancet. Haematology|November 21, 2017
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot studyBerend Snijder, Gregory I Vladimer, Nikolaus Krall, et al.
International Journal of Cancer|October 9, 2020
Thyroid and androgen receptor signaling are antagonized by μ-Crystallin in prostate cancerOsman Aksoy, Jan Pencik, Markus Hartenbach, et al.
Nature Medicine|October 16, 2012
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomasDaniela Laimer, Helmut Dolznig, Karoline Kollmann, et al.
Haematologica|May 25, 2019
High activation of STAT5A drives peripheral T-cell lymphoma and leukemiaBarbara Maurer, Harini Nivarthi, Bettina Wingelhofer, et al.
Cancer Cell|April 16, 2015
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphomaRamona Crescenzo, Francesco Abate, Elena Lasorsa, et al.
Molecular Cancer|October 15, 2025
Thyroid hormone receptor beta signaling is a targetable driver of prostate cancer growthAleksandra Fesiuk, Daniel Pölöske, Elvin D de Araujo, et al.
Pageof 27